IMAGING COLORECTAL CANCER WITH TC 99M VIP

描述：研究人员建议测试开发一种 基于Tc-99 m标记的血管活性肠肽的放射性药物， 如进一步描述的，在具有过表达的肿瘤上的受体特异性摄取 他们的抽象： “每年有超过165，000例新的结直肠癌病例被诊断出来， 美国.它是该国癌症相关死亡的第三大原因。一 对文献的调查得出的结论是， 开发Tc-99 m标记受体特异性药物用于早期诊断 结直肠癌及其转移性病变。早期发现将促使 用于外科手术和/或积极的治疗干预， 发病率和死亡率。 “文献中有大量证据表明血管活性肠肽 (VIP)受体在结肠直肠癌细胞上高密度表达， 肿瘤及其转移病灶可以有效地成像， I-123-VIP。 “我们制备了VIP类似物TP 3654， 试剂盒程序。产率定量，试剂稳定， 不包括生物活性。荷人结肠直肠癌小鼠中的结果 癌症LS 174 T也表明肿瘤摄取是受体特异性的， 肿瘤是通过放射成像来描绘的。我们的具体目标是：1） 通过使用高比活性制剂来增强肿瘤摄取，2） 通过预注射或共注射赖氨酸使肾摄取最小化，3）比较 Tc-99 m TP 3654与最近批准的TC-99 m-抗CEA扫描的疗效， In-111-DTPA-（D）-Phe-奥曲肽和4）测定该受体的受体特异性。 用于其他人结肠直肠细胞系的体外试剂。我们将一起学习 更多关于细胞表面受体如何用于早期检测 并引导我们开发Tc-99 m标记的VIP类似物TP 3654作为治疗癌症的药物。 结肠直肠癌的影像学检查" 拟议商业应用：不可用

DESCRIPTION: The investigators propose to test the feasibility of developing a radiopharmaceutical based on Tc-99m-labeled vasoactive intestinal peptide for receptor-specific uptake on tumors with over-expression, as further described by their abstract: "Each year more than 165,000 new cases of colorectal cancer are diagnosed in the USA. It is the third cause of cancer-related deaths in the country. A survey of the literature leads to the conclusion that the need exists to develop Tc-99m labeled receptor specific agents for early diagnosis of colorectal cancers and their metastatic lesions. Early detection will prompt for surgical and/or aggressive therapeutic interventions and may minimize morbidity and mortality. "Evidence is abundant in the literature that vasoactive intestinal peptide (VIP) receptors are expressed in high density on colorectal cancer cells and that the tumors and their metastatic lesions can be efficiently imaged with I-123-VIP. "We have prepared VIP analog TP 3654 and labeled it with Tc-99m by an instant kit procedure. The yields are quantitative, the agent is stable and its biological activity is not comprised. Results in mice bearing human colorectal cancer LS174T also indicate that the tumor uptake was receptor specific and that tumors were delineated by scintigraphic imaging. Our specific aims are: 1) to enhance tumor uptake by using high specific activity preparations, 2) to minimize renal uptake by pre- or co-injecting lysine, 3) to compare the efficacy of Tc-99m TP 3654 with recently approved TC-99m-anti-CEA scan and In-111-DTPA-(D)-Phe-Octreotide and 4) to determine receptor specificity of the agent for other human colorectal cell lines in vitro. Together, we will learn more about how cell surface receptors can be utilized for early detection of cancer and lead us to develop Tc-99m labeled VIP analog TP 3654 as an agent for imaging colorectal cancer." PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE